

## MyHealthTest Launches Thyroid TSH Test Service

ITL Health Group (ASX:ITD), is pleased to announce that its wholly owned subsidiary MyHealthTest Pty Ltd (MHT), the direct to consumer pathology test provider, has launched a Thyroid TSH Test Service, with immediate effect.

According to Medicare over 5 million TSH tests are performed every year. Thyroid problems are most common in women, with about 10% of all women and up to 25% of women over 65 affected. The thyroid is a small gland in the neck that produces hormones that control metabolism.

The MyHealthTest Thyroid TSH Test Service can indicate an under-active thyroid (hypothyroidism e.g. Hashimoto's thyroiditis). People with low thyroid levels are often prescribed medication to replace the thyroid hormones – usually taken for the rest of their life and are regularly monitored with repeat TSH tests.

MyHealthTest believes demand for its Thyroid TSH Test Service will come from people who find themselves tired and worn out and are unable to find the time to visit the doctor to request a blood test.

MyHealthTest GM Nick Cerneaz 'The Introduction of the Thyroid TSH Test Service is an exciting step for MyHealthTest as we expand our capabilities to help customers and their doctors detect, monitor and manage major chronic diseases.'

The Thyroid TSH Test Service is available through the MyHealthTest online store and will be promoted to both the existing MHT database and to new customers and health care providers. Promotional campaigns will commence in November and roll out through the first quarter of 2018.

Nick Cerneaz continued "We anticipate launching two more test services, for Prostate and Cholesterol in the very near future. These new test services will bring MyHealthTest's portfolio to four, each seeking to meet substantial pre-existing demand for more convenient testing that is used to help monitor and manage these chronic conditions."

### About MyHealthTest

MyHealthTest, a highly innovative consumer-based pathology testing service, allows individuals to conveniently order the test service online, collect fingerpick samples at home, and send samples through the mail for laboratory analysis. Our next-generation pathology testing service is quality controlled to ensure accuracy and reliability, while our online portal offers guaranteed confidentiality and the simple transfer of results to healthcare practitioners or others. MyHealthTest meets the increased global demand for pathology testing services and sets the industry standard for preventative and convenient direct-to-consumer healthcare services.

### ITL Health Group

ITL is an innovative global medical technology company made up of two divisions; ITL BioMedical and MyHealthTest. ITL holds an IP portfolio of more than 50 patents and sells into 55 countries.

ITL BioMedical creates and manufactures leading edge medical devices for the clinical, blood banking, and laboratory markets and is a growing provider of specialist ancillary products for the blood culture testing market.

MyHealthTest creates and markets highly innovative direct to consumer pathology testing for major chronic diseases.



Ranked 16<sup>th</sup> most Innovative Company by the  
AFR Innovative Companies Awards

Australian Securities Exchange  
Code: ITD

Ordinary shares  
97,784,883

#### Board of Directors

Bill Mobbs	Executive Chairman
Mark Peatey	Non-executive Director
Andrew Turnbull	Non-executive Director
Trevor Doolan	Chief Financial Officer & Company Secretary

#### ITL Contact

Trevor Doolan	Company Secretary
Phone:	+61 3 8773 3050
Email:	<a href="mailto:info@itlhealthgroup.com">info@itlhealthgroup.com</a>
Address	Unit 1, 63 Wells Road Chelsea Heights, Victoria, 3196

[www.itlhealthgroup.com](http://www.itlhealthgroup.com)

#### Media

Walbrook IR	Ben Knowles
Phone:	+61 426 277 760
Email:	<a href="mailto:ben.knowles@walbrookir.co.au">ben.knowles@walbrookir.co.au</a>